In colorectal and pancreatic cancers, the TGF-β signalling pathway is frequently abolished by mutations in SMAD4 or TGFBR2 (Massagué, 2008; Levy and Hill, 2006). This evidence concerns the gene SMAD4 and pancreatic neoplasm.